Critical care of the morbidly obese

Critical Care Nursing Quarterly

Volumn 26, Issue 2, 2003, Pages 105-116

  Davidson, Judy E ^a   Kruse, Michael W ^b   Cox, Deborah H ^c   Duncan, Ron ^d  

^a Pomerado Hospital   (United States)

^b Palomar Medical Center   (United States)

^c North Ridge Medical Center   (United States)

^d PALOMAR POMERADO HEALTH   (United States)

Author keywords

Bariatric surgery; Critical care; Morbidly obese; Post operative care; Weight loss surgery

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ATRACURIUM; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; DALTEPARIN; DIAZEPAM; DROTRECOGIN; ENOXAPARIN; GENTAMICIN; HEPARIN; LORAZEPAM; LOW MOLECULAR WEIGHT HEPARIN; NEUROMUSCULAR BLOCKING AGENT; PENICILLIN DERIVATIVE; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEDATIVE AGENT; TINZAPARIN; VANCOMYCIN; VECURONIUM;

BARIATRIC SURGERY; HUMAN; IMMOBILIZATION; INTENSIVE CARE; MORBID OBESITY; NURSING; POSTOPERATIVE CARE; REVIEW; STANDING; SURGICAL PATIENT; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

EID: 0037398347     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200304000-00005     Document Type: Review

References (30)

1. Pizzorno JE, Murray MT. B vitamins. In: Textbook of Natural Medicine. Churchil Livingstone, New York, NY; 1999:917-919.
2. Pizzorno JE, Murray MT. CO-Q10. In: Textbook of Natural Medicine. 1999;663-671.
3. Nakamura R, Littaru GP, Folkers K, Wilkinson EG. COQ-10. Proc Natl Acad Sci. 1985;82:901-904.
4. Pizzorno JE, Murray MT. Flax seed oils. In: Textbook of Natural Medicine. 1999;112, 1139.
5. Pizzorno JE, Murray MT. Selenium, zinc, manganese, magnesium. In: Textbook of Natural Medicine. 1999;920-926.
6. Kritchevsky D. Vitamin E. Nutr Today. 1992;27:1-4.
7. Byrne TK. Complications of surgery for obesity. Surg Clin N Am. 2001;81:1181-1193.
8. MacGregor MI, Bock AJ, Ball WC: Topics in clinical medicine: serious complications and sudden death in the Pickwickian syndrome. Hopkins Med J. 1970;189:279-295.
9. Serafini FM, MacDowell AW, Rosemurgy AS. Clinical predictors of sleep apnea in patients undergoing bariatric surgery. Obes Surg. 2001;11:28-31.
10. Pelosi, P; Caironi P, Bottino N. Respiratory function in obese patients. RT Magazine, Fall 2002.
11. Zerah F, Harf A, Perlemuter L, Lorino H, Lorino AM, Atlar G. Effects of obesity on respiratory resistance. Chest. 1993;103:1470-1476.
12. Gillet R, Demeilliers G, Briel A, Jusserand D, Dureuil B. Effect of bi-level positive airway pressure (BiPAP) nasal ventilation on the postoperative pulmonary restrictive syndrome in obese patients undergoing gastroplasty. Chest. 1997;111:665-670.
13. Eriksen J, Andersen J, Rasmussen JP, Soresen B. Effects of ventilation with large tidal volumes or positive end-expiratory pressure on cardiorespiratory function in anesthetized obese patients. Acta Anaesthesiol Scand. 1978;22:241-248.
14. Pelosi P, Ravagnan I, Giurati G. Positive end-expiratory pressure improves respiratory functions in obese patients but not in normal subjects during anesthesia and paralysis. Anesthesiology. 1999;91:1221-1231.
15. Cheymol G. Clinical pharmacokinetics of drugs in obesity. Clin Pharmacokinet. 1993;25:103-114.
16. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. Clin Pharmacokinet. 1986;11:199-213.
17. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm. 1998;55:159-162.
18. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87:817-823.
19. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol. 2000;56:293-297.
20. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308-318.
21. Wilson SJ, Wilbur K, Burton E, et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31:42-48.
22. Inverso SM, Cohen M, Antman EM, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. J Am Coll Cardiol. 2001;37:365A.
23. Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg. 2001;11:670-676.
24. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997;25:112-118.
25. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet. 2000;38:415-426.
26. Kanto J, Gepts E. Pharmacokinetic implications for the clinical use of propofol. Clin Pharmacokinet. 1989;17:308-326.
27. Data on file. Indianapolis, Ind: Eli Lilly & Co; July 19, 2002.
28. Griffen WO, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass. Arch Surg. 1997;112:799-806.
29. Davidson JE, Callery C. Care of the obesity surgery patient requiring intermediate level or intensive care. Obes Surg. 2001;11:93-97.
30. Davidson JE, Callery C. Making the most of your time: the benefits of converting patient education programs into continuing nursing education. Obes Surg. 2000;10:482-483.